EODData

MEMBERSHIP REGISTER LOG IN

LSE, VRCI: Verici Dx PLC

05 Sep 2025
LAST:

0.5050

CHANGE:
 0.02		OPEN:
0.5100		HIGH:
0.5500		ASK:
0.0000		VOLUME:
1.46M
CHG(%):
3.81		PREV:
0.5250		LOW:
0.5000		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Sep 250.51000.55000.50000.50501.46M
04 Sep 250.55000.55000.50000.52501.35M
03 Sep 250.51700.55000.50000.5250981.3K
02 Sep 250.50000.52500.50000.5250152.3K
01 Sep 250.48000.55000.48000.52501.74M
29 Aug 250.50000.50100.50000.501052.3K
28 Aug 250.50000.52500.50000.52501.06M
27 Aug 250.52500.52500.52500.5250200.2K
26 Aug 250.50100.55000.50000.5250697.8K
25 Aug 250.52500.50100.50000.5250313.4K

COMPANY PROFILE

Name:Verici Dx PLC
About:Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs, and functional binding multicell assay. In addition, the company provides bioinformatics and data science services for exome analysis options; RNA pipeline; multiomic signature discovery, TCR clonotype antigen identification, custom pipeline building, and predictive modeling; and simulation of 100s of drug combinations against multiomic personalized tumor models. It has collaborations with One Lambda Inc. for the commercialization of pre transplant risk assessment (PTRA), a pre-transplant prognosis test for the risk of early acute rejection; The Westmead Institute for Medical Research to determine the factors contributing to graft loss in organ transplants; and FBB Biomed, Inc., which provides research-use-only tests for clinicians seeking insights into neurologic diseases, such as multiple sclerosis and long COVID. Verici Dx plc was incorporated in 2020 and is based in Cardiff, the United Kingdom.
Sector:Healthcare
Address:Avon House, Cardiff, United Kingdom, CF64 2EZ
Website:https://vericidx.com
ISIN:GB00BM8HZD43
LEI:213800FI5WE4FVQ3G645

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.52
MA10:0.52
MA20:0.52
MA50:0.71
MA100:1.06
MA200:2.13
STO9:8.16
STO14:10.00
RSI14:41.53
WPR14:-80.00
MTM14:-0.02
ROC14:-0.04
ATR:0.03
Week High:0.55
Week Low:0.48
Month High:0.60
Month Low:0.47
Year High:7.00
Year Low:0.47